



The Islamic University of Gaza 
Deanship of Post graduate Studies 






   Serum Vitamin D Level in Chronic Kidney 




Submitted in Partial Fulfillment for the Master Degree of 




Soha  A. Abdallah  






Prof. Dr. Maged M. Yassin 
Professor of Physiology 
Faculty of Medicine 












I hereby declare that this submission is my own work and that, to the best of 
my knowledge and belief, it contains no material previously published or 
written by another person nor material which to a substantial extent has been 
accepted for the award of any other degree of the university or other institute, 







Signature                                 Name                                        Date 








All rights reserved © 2014: No part of this work can be copied, translated or 






I dedicate this work to: 
My beloved parents who have always supported me 
My Husband who encouraged me to accomplish this thesis 
to my brothers 
All researchers who are working to improve the quality of life 
Dedication is almost expressed to the Palestinian people who 
have suffered and are struggling with the persistence to                  
have a free Palestine. 
  















I would like to express my deepest gratitude and appreciation to my 
supervisor Prof. Dr Maged M. Yassin, Professor of Physiology, Faculty of 
Medicine, The Islamic University of Gaza for his planning and initiating of this 
work and for his continuous support, encouragement and kind of supervision 
that leads to the emergence of this work in its current form. 
 
Special thanks for the dearest persons to me my mother, my father and my 
Husband Dr.Alaa for their support and encouragements.  
 
I would like to thank the staff of kidney disease unit in AL-Shifa hospital and 
Nasser Medical Complex for their facilitation and helping me in samples 
collection. 
 
My special thanks to Mr. Abed EL- Rahman Hamad for his help in statistical 
analysis. 
 
At the end, I am very grateful to every person who participated and helped me 







Serum vitamin D level in chronic kidney disease 




Background: chronic kidney disease (CKD) is one of the leading cause of 
death among the Palestinians. Although vitamin D deficiency has been 
recently linked to CKD, biochemical tests in Gaza hospitals and clinics are 
restricted to monitoring kidney function by routine tests. Therefore, introducing 
vitamin D test for CKD patients may be helpful in understanding patient’s 
condition and help in disease management. 
Objective: To assess serum vitamin D level in CKD patients from Gaza Strip. 
Material and methods: This case-control study comprised 42 CKD patients 
and 42 healthy controls. Patients were taken from Kidney unit in Al-Shifa 
hospital and Nasser Medical Complex in Gaza Strip. Controls were selected 
from the general population. Questionnaire interview was applied. Serum 
vitamin D, urea, creatinine, uric acid, glomerular filtration rate (GFR), total 
protein, albumin, globulin, calcium and phosphorus were determined. Data 
were analysed using SPSS version 18.0. 
Results: The mean ages of cases and controls were 55.3±8.6 and 54.9±8.2 
years, respectively. CKD was more frequent among unemployed individuals,  
families with low income as well as among families with history of CKD 
(P<0.05). The mean levels of vitamin D were significantly lower in cases 
compared to controls (29.7±12.9 versus 35.2±9.9 ng/dl, P=0.033). Serum 
urea, creatinine and uric acid were found to be significantly higher in cases 
(84.6±47.4 and 1.90±1.20 and 7.92±2.29 mg/dl, respectively) compared to 
controls (35.7± 13.5 and 0.81±0.27 and 5.18±2.31 mg/dl) with P=0.000. In 
contrast, The mean value of GFR was significantly declined in cases 
compared to controls (62.4±32.5 versus 124.6±45.4, P=0.000). There was a 
significant decrease in serum total protein and albumin in cases compared to 
controls (7.0±0.5 and 5.2±0.40 versus 7.3±0.6 and 5.4±0.59, P=0.005 and 
P=0.023, respectively). Serum calcium was significantly declined in cases 
compared to controls, whereas serum phosphorus showed none significant 
increase in cases (8.61±0.77 versus 9.12±0.69, P=0.003 and 4.72±0.94 
VI 
 
versus 4.49±0.85, P=0.239, respectively). Vitamin D level was found to be 
significantly lower in individuals with family history of CKD (P=0.038). Vitamin 
D levels were positively correlated with GFR (r=0.258, P=0.020), total protein 
(r=0.283, P=0.011), albumin (r=0.278, P=0.012), globulin (r=0.159, P=0.156) 
and calcium (r=0.562, P=0.001) and negatively correlated with urea (r=-0.302, 
P=0.005), creatinine (r=-0.343, P=0.001), uric acid (r=-0.249, P=0.022) and 
phosphorus (r=-0.168, P=0.125).  
Conclusions: Serum vitamin D levels were significantly lower in CKD patients 
compared to controls. Vitamin D levels were lower in individuals with family 
history of CKD. Vitamin D levels were positively correlated with GFR, total 
protein, albumin, globulin and calcium, and negatively correlated with urea, 
creatinine, uric acid and phosphorous. 
Keywords: Chronic kidney disease, Vitamin D, Gaza strip.
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احد اسباب الوفاة بين الفلسطينيين. وعلى الرغم من ارتباط نقص فيتامين د بقوة تعد امراض الكلى  :المقدمة
بمرض الكلى المزمن, اال ان الفحوصات التى تعمل لهذا المرض محدودة. لذلك ادخال اختبار فيتامين د في 
 .المرضحالة المريض وتساعد في ادارة فهم يساعد في مستشفيات غزة لمرضى الكلى 
 في قطاع غزة. المزمنة الكلى امراضستوى فيتامين د في : تقييم مالهدف
مجموعة ضابطة( المجموعة المرضية تحتوى على -منهج الدراسة ) مجموعة مرضية الطرق واالدوات:
الحاالت تم اخذها من  امراة(.22 -رجل 22شخصا من االصحاء ) 42امراة(, 22 -رجل22)مريض كلى  42
. وقد تم الحصول على النتائج من اما االصحاء تم اخذهم من المجتمع ,الطبى ناصر و مجمعمستشفى الشفاء 
خالل المقابلة الشخصية للمرضى واالصحاء, وتم قياس مستوى فيتامين د, اليوريا, الكرياتينين, حمض اليوريك 
تائج باستخدام , معدل الترشيح الكبيبى, والبروتين وااللبيومين والكالسيوم والفوسفور, وقد تم تحليل البيانات والن
 .SPSS-18البرنامج االحصائى 
سنة على  4.5.±6.2و  5...±6.8متوسط االعمار حاالت والضوابط هو  تبين من الدراسة ان النتائج:
واالفراد الذين لديهم  مرض الكلى المزمن اكثر شيوعا بين الغير عاملين وذوى الدخل المنخفضوان  ,التوالى
متوسط مستوى فيتامين د في الحاالت اقل بكثير مقارنة مع الضوابط.  . كانتاريخ عائلى في مرض الكلى
مستويات اليوريا والكرياتينين وحمض اليوريك كانت مرتفعة بشكل ملحوظ في الحاالت مقارنة مع الضوابط. 
منخفض في الحاالت مقارنة مع الضوابط. وقد انخفض مستوى  GFRكان مستوى معدل الترشيح الكبيبى
كما انخفض معدل الكالسيوم  في الدم بشكل ملحوظ في الحاالت مقارنة مع الضوابط.لبيومين واالالبروتين 
 وارتفع الفوسفور.
واظهرت النتائج وجود عالقة ايجابية بين مستوى فيتامين د مع مستوى معدل الترشيح الكبيبى والبروتين 
وريا والكرياتينين وحمض اليوريك وااللبيومين والجلوبيولين والكالسيوم, وعالقة سلبية مع كل من الي
 والفوسفور.
 
 قطاع غزة., الكلى المزمن, فيتامين د ىمرض الكلمات المفتاحية:
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1.1 Overview   
Chronic kidney disease (CKD) is a modern day global epidemic and it is now 
recognized as a public health issue. Chronic kidney disease is defined as 
either kidney damage or glomerular filtration rate (GFR) <60 mL/min/1.73 m2 
for >3 months or more, irrespective of cause (Levey et al., 2005;  Eckardt et 
al., 2009 and Levey et al., 2011). Kidney damage in many kidney diseases 
can be ascertained by the presence of albuminuria (Guh, 2010). The severity 
of CKD is classified into five stages according to the level of GFR, with stage 
1 (GFR≥90 ml/min/1.73m2) being the mildest and usually causing few 
symptoms and stage 5 (GFR<15 ml/min/1.73m2 or dialysis) being a severe 
illness with poor life expectancy if untreated (National Kidney Foundation, 
NKF, 2002;  Bauer et al., 2008 and Levey and Coresh, 2012). 
  
Most epidemiological information on CKD originates from data available on 
end stage renal disease (ESRD). Little information is available on the 
prevalence of earlier stages of CKD, as patients are often asymptomatic 
(Warady and Chadha, 2007). Centers for Disease Control and Prevention 
(CDC) have estimated that more than 10% of adults in USA, more than 20 
million people, may have CKD (CDC, 2014). United Kingdom estimates  
suggested that the prevalence of CKD was 8.5% (Stevens et al., 2007). In 
Egypt the prevalence of CKD was estimated at 10.6% (Gouda et al., 2011). In 
Jordan, ESRD accounted for around 3% of the population (The Hashemite 
kingdom of Jordan, Ministry of Health, 2008). Renal failure is the 6th 
leading cause of death in Palestine (Ministry of Health, MOH, 2010). The 
total prevalence of  ESRD among Palestinian patients in West Bank was 
240.3 per million population (Khader et al., 2013). 
 
The risk factors for developing CKD include diabetes mellitus, hypertension, 
obesity, cardiovascular disease, family history of CKD and age over 60 years 
(Stenvinkel, 2010; Huda et al., 2012 and CDC, 2014). Most people may not 
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have any severe symptoms until their kidney disease is advanced. However, 
the symptoms of chronic kidney disease may include tiredness, troubles in 
concentration, poor appetite, troubles in sleeping, muscle cramping at night, 
swollen feet and ankles, puffiness around eyes especially in the morning, 
have dry and itchy skin, and need to urinate more often especially at night 
(Wiggins and Johnson, 2012  and NKF, 2013). 
 
Vitamin D is a fat-soluble vitamin that plays an essential role in calcium 
homeostasis and the maintenance of normal function in multiple tissues. 
Humans obtain vitamin D either directly from the diet or through exposure to 
solar ultraviolet B radiation (Holick, 2011 and Kannan and Lim, 2014). In 
addition to its well-recognized effects on skeletal health, vitamin D has 
suggested to have a potential role in other disease states and health 
conditions including chronic kidney disease, cardiovascular disease, type 2 
diabetes, autoimmune disorders and cancer (Drake et al., 2010; Dalgard et 
al., 2011; Joergensen et al., 2012; Satirapoj et al., 2013 and Nigwekar et 
al., 2014). 
 
Recent studies have reported that vitamin D deficiency or insufficiency is 
common in patients with CKD, and serum levels of vitamin D appear to have 
an inverse correlation with kidney disease (Adams and Hewison, 2010; 
Dusso  et al., 2011; Nigwekar et al., 2012; Rozita et al., 2013; Kim and 
Kim, 2014 and Obi et al., 2015). In this regard, it has been shown that 
treatment with active vitamin D or its analogues can ameliorate renal injury 
(Rojas-Rivera et al., 2010 and Kim and Kim, 2014). In addition, impaired 
vitamin D metabolism in CKD was addressed (Bosworth and de Boer, 
2012). 
 
In Gaza strip, studies on vitamin D status in  patients with chronic disease are 
limited. Only two studies related vitamin D to coronary artery disease (CAD) 
and type 2 diabetes in Gaza strip have been recently emerged (Elhenawe, 
2014 and Masoud, 2014). No previous study linked vitamin D to CKD. 
Therefore, the present study is the first to assess serum vitamin D level in 




1.2 General objective 
To assess serum vitamin D level in CKD patients from Gaza strip. 
 
1.3 Specific objectives  
1. To determine vitamin D level  in cases compared with controls. 
2. To estimate kidney function through determination of urea, creatinine 
,uric acid and GFR in cases and controls. 
3. To test serum total protein, albumin and globulin in cases in 
comparison with controls 
4. To evaluate serum calcium and phosphorus in cases and controls 




1. Chronic kidney disease is being increased worldwide. In Palestine, renal 
failure is the 6th leading cause of death (National Health Service, NHS, 
2010). 
2. In Gaza Strip only three studies have been investigated vitamin D status in  
patients with chronic disease (Elhenawe, 2014, Masoud, 2014 and 
Elhamalawy, 2015). To my best knowledge, no previous study linked vitamin 
D to CKD. Therefore, as far as I know this is the first study to assess serum 
vitamin D level in CKD patients in Gaza Strip. 
3. Treatment of CKD patients with vitamin D could be useful in the disease 














2.1 The kidneys 
2.1.1 Location and structure 
The kidneys are small, dark red organs lie against the dorsal body wall 
beneath the parietal peritoneum in superior lumbar region where they receive 
some protection from the lower part of the rib cage (Figure 2.1). An adult 
kidney (about 12 cm long, 6 cm wide, and 3 cm thick) has a medial 
indentation (the hilus) in which there are renal artery, renal vein, and ureter 
(Marieb, 2003). The kidney has three regions, outer granulated layer called 
renal cortex, renal medulla that consists of cone shaped tissue masses called 
medullary pyramids, and renal pelvis which is a central space or cavity that is 









Each kidney contains approximately one million tiny structures called 
nephrons (Figure 2.2). Nephrons are responsible for the processes of 
filtration, reabsorption, and secretion that go on in the kidney to form the urine 
product (Marieb, 2003). The nephron consists of two main structures, a 
glomerulus, which is a knot of capillaries, and a renal tubule. The closed end 
of the renal tubule is enlarged and cup-shaped and completely surrounds the 
glomerulus. This portion of the renal tubule is called Bowman's capsule. In 
order from Bowman's capsule they are the proximal convoluted tubule, loop of 
Henle, and the distal convoluted tubule. Most of the nephron is located in the 
cortex, only portion of the loops of Henle dip into the medulla. Urine from 
many nephrons is collected in the collecting ducts, which deliver the final urine 
product into the calyces and pelvis of the kidney (Thibodeau and Patton, 
1999; Mader, 2004 and Guyton and Hall, 2011). 
 
 








2.1.2 Functions of the kidney   
The kidneys excrete natural waste products, including urea and creatinine, as 
well as foreign substances like alcohol and drugs, from the body. The kidneys 
also play a role in water level balancing and acid regulation (Faratro et al., 
2004). The kidneys also produce and secrete important hormones including 
renin, erythropoietin and vitamin D. Renin is involved in regulating blood 
pressure, erythropoietin is used to stimulate the bone marrow to produce red 
blood cells, and vitamin D is needed to absorb the calcium from food in the 
intestine (Faratro et al., 2004 and Barret et al., 2010). 
 
2.2  Chronic kidney disease 
2.2.1 Definition  
The National Kidney Foundation (2002) defines CKD as ″kidney  damage 
for ≥ 3 months, as confirmed by kidney biopsy or markers of kidney damage, 
with or without a decrease in GFR or GFR < 60 ml/min/1.73 m2 for ≥ 3 
months, with or without kidney damage″. Kidney damage is ascertained by 
either kidney biopsy or markers of kidney damage, such as urine 
abnormalities (proteinuria), blood abnormalities or abnormalities on imaging 
studies. 
 
Levey et al. (2005) defined CKD as kidney damage or GFR <60 ml/min/1.73 
m2 for 3 months or more, irrespective of cause. Kidney damage in many 
kidney diseases can be ascertained by the presence of albuminuria, defined 
as albumin-to-creatinine ratio >30 mg/g in two of three spot urine specimens. 
Glomerular filtration rate can be estimated from calibrated serum creatinine 
and estimating equations, such as the modification of diet in renal disease 
study equation or the Cockcroft-Gault formula (table 2.1). 
 
Chronic kidney disease is defined according to a decrease in the GFR and 
kidney damage such as proteinuria (>200 mg/day or protein to creatinine ratio 
(PCR) >200 mg/g creatinine) or albuminuria (urinary albumin excretion (UAE) 




International Society of Nephrology (2013) defined CKD as abnormalities 
of kidney structure or function, present for >3 months, with implications for 
health. Markers of kidney damage (one or more) include: Albuminuria 
(ACR≥30 mg/g), urine sediment abnormalities, electrolyte and other 
abnormalities due to tubular disorders, abnormalities detected by histology, 
structural abnormalities detected by imaging, history of kidney transplantation 
and GFR <60 ml/min/1.73m2. 
 
2.2.2. Glomerular filtration rate 
Glomerular filtration rate describes the flow rate of filtered fluid through the 
kidney. Glomerular filtration rate provides an excellent measure of the filtering 
capacity of the kidneys. A low or decreasing GFR is a good index of CKD 
(Gansevoort et al., 2011; International Society of Nephrology, 2013 and 
Nigwekar et al., 2014). 
 
The level of GFR should be estimated from prediction equations that take into 
account the serum creatinine concentration and some or all of the following 
variables: age, gender, race, and body size (Table 2.1). The following 
equations provide useful estimates of GFR: 
 In children, the Schwartz and Counahan-Barratt equations 
 In adults, the abbreviated modification of diet in renal disease (MDRD) 
study equation and Cockcroft-Gault equations (NKF, 2002). 
 
Table 2.1 Prediction of GFR based on serum creatinine 
Authorۥs equation Equation 
Schwartz GFR (ml/min/1.73m²) =  0.55×length  ∕ Scr 
Counahan-Barratt GFR (ml/min/1.73m²) =  0.43 × length  ∕ Scr 
Abbreviated MDRD Study GFR(ml/min/1.73m²)=186×(Scr)×(Age)×(0.742 
if female) × (1.210 if black) 
Cockcroft-Gault Ccr (ml/min) = (140 –Age)×Weight ×(0.85 if 
female ) ∕ 72× Scr 




2.2.3 Classification of chronic kidney disease 
Chronic kidney disease has been classified into various stages for the 
purpose of prevention, early identification of renal damage and institution of 
preventive measures for progression of the primary damage and appropriate 
guidelines for instituting management for prevention of complications in 
severe CKD (Vijayakumar et al., 2007). National Kidney Foundation (2002) 
classified CKD into 5 stages according to the level of GFR (Table 2.2). For 










1 Kidney damage with normal or 
increased GFR 
≥ 90 
2 Kidney damage with mild 
reduction of GFR 
60-89 
3 Moderate reduction of GFR 30-59 
4                       Severe reduction of GFR 15-29 
5 Kidney failure (ESRD) <15 or dialysis 
GFR: Glomerular filtration rate. ESRD: End stage renal disease. 












2.2.4 Epidemiology of chronic kidney disease 
Chronic kidney disease is an important global public health concern because 
of its high incidence, prevalence, morbidity, and mortality (Levey et al., 2007). 
Until recently, little has been known about the epidemiology of pre-ESRD. The 
main reason for this includes the absence of any systematic, population-
based collection of data on CKD (McClellan et al., 2006). It is estimated that 
by 2030, over 70% of patients with ESRD will be inhabitants of developing 
countries, probably related to the fast rising trend of obesity and diabetes in 
these countries (Barsoum, 2006 and Motlagh et al., 2009). 
 
Centers for Disease Control and Prevention have estimated that more than 
10% of adults in USA, more than 20 million people, may have CKD (CDC, 
2014). United Kingdom suggested that the prevalence of CKD was 8.5% 
(Stevens et al., 2007). In Canada, 1.9-2.3 million people have CKD (Levin et 
al., 2007). In Japan, the prevalence of CKD constitutes approximately 13% of 
the adult population (Nakai et al., 2013). In addition, CKD may affect up to 
7.7% of the korean population resulting in high morbidity and mortality (Shin 
et al., 2014). 
 
The reported prevalence of CKD in Arab world is very limited. In Egypt the 
prevalence of CKD was estimated at 10.6% (Gouda et al., 2011). In Jordan, 
ESRD accounted for around 3% of the population (The Hashemite kingdom 
of Jordan, Ministry of Health, 2008). In Saudi Arabia, the prevalence of CKD 
in the young Saudi population is around 5.7% (Alsuwaida et al., 2010). 
 
The Palestinian 2005 report showed that the prevalence of renal failure was 
4% with an incidence of 10.8 per 100,000, distributed as 1.1% in Gaza strip 
and 2.9% in the West Bank (MOH, 2005). Recent study showed that the total 
prevalence of  ESRD among Palestinian patients in West Bank was 240.3 per 
million population (Khader et al., 2013). 
 
 2.2.5 Risk factors of chronic kidney disease 
The most common risk factors for CKD include socioeconomic status, family 
history, obesity, diabetes, hypertension. 
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2.2.5.1 Socioeconomic status 
Socioeconomic factors are known to influence both the prevalence and 
severity of CKD. Zhang et al. (2012) reported that the prevalence of CKD 
varied greatly between geographical regions and this might be related to 
variability in lifestyles and economic development. Several studies have 
demonstrated an increased risk of CKD in individuals of lower socioeconomic 
status (Drey et al., 2003; Ward, 2008; McIntyre et al., 2011 and Abu Nada, 
2012). However, the determinants of progression of CKD are not fully 
understood though there are a number of proposed risk factors including 
socioeconomic factors for its progression (Stringer et al., 2013). 
 
2.2.5.2 Family history 
Genetic predisposition plays an important role in CKD. Most studies indicated 
that family history is a risk factor of CKD (Levey et al., 2005; Hsu et al 2009; 
Baumgarten and Gehr, 2011 and CDC, 2014). In a cohort of 1742 people 
participating in community-based CKD screenings, 24% reported a family 
history of kidney disease and 60% tested positive for microalbuminuria 
(Harward et al., 2009). In addition, the prevalence of CKD in first-degree 
relatives is high, estimated as three-fold higher than for a general population 
as reported in population studies (Inserra et al., 2007). 
 
2.2.5.3 Obesity 
Obesity as defined by increased body mass index (BMI) has been reported to 
be associated with increased risk of developing CKD (Wang et al., 2008; 
Nugent et al., 2011 and CDC, 2014). It is estimated that by 2030, over 70% 
of patients with ESRD will be inhabitants of developing countries, probably 
related to the fast rising trend of obesity in these countries (Barsoum, 2006 
and Motlagh et al., 2009). BMI is shown to be inversely related to GFR 
(Kramer, 2006 and Ishizaka et al., 2007). In this regard, Hyun et al. (2014) 
found that fat mass gain over 5 years was independently associated with GFR 
decline to <60 ml/min/1.73m2 in a relatively healthy Korean population. It was 
reported that adipose tissue produces a variety of hormones and 
proinflammatory molecules that may contribute to progressive renal damage 




2.2.5.4 Diabetes mellitus 
Metabolic diseases such as diabetes are known to be a risk factor of kidney 
injury and plays an important role in the progression of CKD. Most studies 
pointed out that diabetic patients have a high risk of developing CKD (Chen et 
al., 2007; Nugent et al., 2011 and Maryam et al., 2012). In addition, diabetes 
is one of the leading cause of CKD in the developed countries. Approximately 
40% of diabetic patients had some degree of CKD in the United States 
(Laliberté et al., 2009) and 40–50% of diabetic patients had kidney injury in 
Japan (Ohta et al., 2010). In general, it is accepted that about 1 of 3 adults 
with diabetes has CKD (CDC, 2014). Diabetes mellitus is likely to cause 




Hypertension is a major risk factor for the development of CKD and 
progression to ESRD (NKF, 2007; Nugent et al., 2011 and Johnson et al., 
2013). In this regard, CDC reported that approximately 1 of 5 adults with high 
blood pressure has CKD (CDC, 2014). An increase in diastolic arterial blood 
pressure was associated with slightly reduced GFR in the middle-aged 
healthy general population. This may be consistent with the hypothesis of a 
renal cause of essential hypertension, but can also be explained by renal 
damage caused by elevated blood pressure (Mathisen et al., 2010). In 
addition, hypertension and diabetes may interact synergistically to increase 









2.3 Vitamin D 
2.3.1 Definition  and structure 
Vitamin D is a seco-steroid hormone and it is critically important for the 
development, growth and maintenance of a healthy skeleton from birth until 
death (Andersen et al., 2007). Vitamin D has other roles in human health; it 
can play a role in decreasing the risk of many chronic illnesses, including 
chronic kidney disease, cardiovascular disease, diabetes, autoimmune 
diseases and cancer (Zhang and Naughton, 2010; Nigwekar et al., 2012;  
Grober et al., 2013 and Nigwekar et al., 2014). The molecular structure of 
vitamin D is closely allied to that of classic steroid hormones in that it has the 
same root cyclopentanoperhydrophenanthrene ring structure (Figure 2.3, 





Figure 2.3. Structure of vitamin D  (Wang, 2013). 
 
 
2.3.2 Sources of Vitamin D 
Vitamin D is obtained either directly from the diet or by means of 




1. Dietary sources of vitamin D (exogenous vitamin D) 
Fish, liver oils, fatty saltwater fish, dietary products and eggs all contain 
vitamin D. It is also found in butter, cod liver oil, dandelion green, egg yolks, 
halibut, liver, milk, oatmeal, salmon, sardines, sweat potatoes, tuna and 
vegetables (Balch, 2001; Palomer et al., 2008 and Holick, 2011).  
2. Photosynthesis in the skin (endogenous vitamin D) 
The solar ultra violet B radiation penetrates the skin to convert 7-
hydrocholesterol to previtamin D3, which is thermodynamically unstable and 
undergoes thermally induced conversion to vitamin D3 (Figure 2.4). Whatever 
the source, vitamin D3 must be hydroxylated twice to produce the biologically 
active form. Thus, the first hydroxylation process takes place in the liver and 
forms 25-hydroxyvitamin D3 and is catalysed by vitamin D-25-hydroxylase. 
The second hydroxylation step, which produces the final active metabolite of 
vitamin D3 (1,25(OH)2D3), is mediated by 25-hydroxyvitamin D3 1-
hydroxylase and occurs predominantly in the kidney. Then, 1,25(OH)2D3 is 
released into the circulation where it binds to vitamin D-binding protein until it 
reaches its target tissue by means of the vitamin D receptors (Chagas et al., 











Figure 2.4  Synthesis of vitamin D. UVB: Ultra Violet B, 25(OH)D3: 25-hydroxyvitamin 
D3,  25-OHase: Vitamin D-25-hydroxylase, 1-OHase: 25-hydroxyvitamin D3 1α-
hydroxylase, DBP: Vitamin D-binding protein (Palomer et al., 2008). 
21 
 
2.3.3. Mechanism of action of vitamin D 
Vitamin D is bound to vitamin D-binding protein in circulation, crosses the cell 
membrane, and binds to vitamin D receptor (Figure 2.5). The conjugated 
vitamin D with its receptor forms a heterodimer complex with retinoid X 
receptor and with other factors, attaches to vitamin D–responsive elements 
on deoxyribonucleic acid, and alters gene expression. It has been estimated 
that vitamin D regulates more than 200 genes, directly or indirectly, thereby 
influencing a wide variety of physiological processes (Vanga et al., 2010; 
Stivelman and Retnakaran, 2012  and  Wang, 2013). 
 
 
Figure 2.5 Action of vitamin D. DBP: Vitamin D-binding protein, VDR: Vitamin D 
receptor, RXR: Retinoid X receptor, RNA: Ribonucleic acid (Vanga et al. 2010). 
2.3.4. Roles of vitamin D 
Vitamin D has several roles in the body; many of these arise from its action on 
gene transcription and expression. In addition to the well-recognized effects of 
vitamin D on skeletal health, emerging evidence suggests a potential role for 
vitamin D in numerous other disease states and health conditions including 
chronic kidney disease, cardiovascular disease, type 2 diabetes, autoimmune 
disorders and cancer.  
21 
 
2.3.4.1 Bone health and calcium absorption 
Vitamin D facilitates calcium absorption in the intestine by influencing the 
expression of epithelial calcium channels and thus calcium-binding proteins. 
This process allows calcium to be better absorbed from the foods eaten 
(Holick, 2005). Due to the increase in absorption on calcium, parathyroid 
hormone (PTH) levels are better regulated. When serum calcium levels are 
low, the parathyroid gland secretes PTH, which leads to increased production 
of vitamin D. This further increases absorption of calcium from the intestine as 
well as increases reabsorption of calcium by the kidneys. The third effect that 
increased PTH levels have on the body is that it leads to resorption of calcium 
from the bone in order to maintain adequate serum levels. Leaching calcium 
out of the matrix of bone leads to decreased bone strength. If adequate 
vitamin D is present before this occurs, PTH levels are likely to be kept low as 
calcium absorption is increased (Wacker and Holick, 2013). Another way in 
which vitamin D works to increase bone strength is by mediating the 
incorporation of calcium into the matrix of bone. This strengthens the network 
of fibers within the bone itself thus leading to stronger bones (Reese, 2006).  
 
2.3.4.2. Vitamin D and chronic kidney disease 
Vitamin D deficiency is commonly observed across the spectrum of chronic 
kidney disease stages (Williams et al., 2009; Holden et al., 2010; Satirapoj 
et al., 2013 and Obi et al., 2015). In this regard, Kendrick et al. (2012) found 
that low plasma concentrations of vitamin D were associated with 1.2 and 1.6-
fold risk of death and progression to chronic dialysis. In addition, Pilz et al. 
(2011) demonstrated a relationship of low vitamin D with mortality and 
cardiovascular event rate in both dialysis and pre-dialysis patients. 
Supplementation of vitamin D or its analogs have been shown to slow the 
progression of CKD (Shoben et al., 2008; Li, 2013; Kim and Kim, 2014 and 
Kim et al., 2014). In this context, observational studies have found that CKD 
patients treated with active vitamin D analogs have a lower risk of death than 
patients who were not treated (Kovesdy et al., 2008). Chronic uremia, 
reduced kidney mass, reduced kidney function or reduced GFR, and protein 
losses are some of the contributors to hypovitaminosis D in CKD (Rojas-




2.3.4.3. Vitamin D and cardiovascular disease 
A growing body of evidence suggests a possible association between vitamin 
D deficiency and many cardiovascular disorders, including hypertension, 
peripheral vascular disease, CAD and heart failure. Vitamin D receptors are 
located on vascular smooth muscle, endothelium, and cardiomyocytes (Wang 
et al., 2008). One of the main mechanisms whereby vitamin D appears to 
decrease cardiovascular disease risk is its effect on hypertension through the 
renin-angiotensin system (Vaidya et al., 2011 and Kienreich et al., 2013). 
Most of studies reported significant inverse relations between vitamin D levels 
and blood pressure (Scragg et al., 2007; Abuannai and O’Keefe., 2011 and 
Kienreich et al., 2013). Vitamin D deficiency is also strongly associated with 
increased thickness of the intima-media in carotid arteries (Targher et al., 
2006 and Joergensen et al., 2012). In this regarded vitamin D was found to 
be associated with atherosclerosis and CVD events (Lavie et al., 2011 and 
Ku et al., 2013). Also, Virtanen et al. (2011) demonstrated an increased risk 
of CAD death in individual with vitamin D deficiency. In addition, Elhenawe, 
(2014) found a progressive decrease in vitamin D level with increasing the 
duration of CAD. 
 
2.3.4.4. Vitamin D and type 2 diabetes 
Most studies have reported a significant inverse association between serum 
vitamin D and the presence of type 2 diabetes (Dalgard et al., 2011; 
Gonzalez-Molero et al., 2012; Djalali et al., 2013 and Mansuri et al., 2014). 
In addition, a number of studies have also investigated the role of vitamin D in 
the primary pathophysiological disorders underlying type 2 diabetes, 
specifically insulin resistance and β-cell dysfunction. A significant inverse 
association of serum vitamin D with insulin resistance was documented 
(Tracy and Mazen, 2010 and Afsaneh et al., 2013). Regarding β-cell 
function, several studies reported a positive association between vitamin D 






2.3.4.5. Vitamin D and autoimmune diseases 
Various epidemiological studies suggested associations between vitamin D 
deficiency and a higher incidence of autoimmune diseases, such as type -1-
diabeties, multiple sclerosis, systemic lupus erythematosus, rheumatoid 
arthritis and inflammatory bowel disease (Grober et al., 2013 and Sabbagh 
et al., 2013). Vitamin D receptors are present in many cell types including 
various immune cells such as antigen-presenting-cells, T cells, B cells and 
monocytes (Prietl et al., 2013). A recent systematic review analyzed results 
from 219 published studies and concluded that vitamin D seems to play a 
beneficial role in the prevention of autoimmunity but that there is still a lack of 
randomized controlled clinical trials in this field (Antico et al., 2012). 
 
2.3.4.6. Vitamin D and cancer 
An inverse association between vitamin D and the incidence of several 
cancers and mortality from these cancers has been shown in case-control 
studies, prospective and retrospective studies (Freedman et al., 2007; Drake 
et al., 2010; Manson et al., 2011; Robsahm et al., 2013 and Ying et al., 
2014), and especially for cancers of the colon, breast and prostate (Holick, 
2007). Several studies show that supplementation with calcium and vitamin D 
reduced the relative risk (RR) of cancer (Lappe et al., 2007 and Crew, 2013). 
The anti-carcinogenic effects of vitamin D could be explained by anti-
proliferative effects on cancer cells by promoting cyclin-dependent kinase 
inhibitor synthesis, and by influencing several growth factors and their 
signaling pathways (Fleet et al., 2012). In addition, vitamin D promotes 
various apoptotic mechanism and cell differentiation and suppresses 
angiogenesis and tumor invasion and metastasis (Deeb et al., 2007; 









2.4 Related studies 
In a cross-sectional analysis of 825 consecutive incident hemodialysis 
patients from 569 unique centers in the United States, Wolf et al. (2007) 
reported that over 3/4th of the cohort was vitamin D deficient (Serum vitamin 
D <30 ng/ml) and about 1/5th of the cohort was severely deficient (Serum 
vitamin D <10 ng/ml). The authors concluded that the prevalence of vitamin D 
deficiency in the CKD population has been described to range between 70 
and 80%. 
 
In an observational study of 226 patients with stage III and IV CKD, Inaguma 
et al. (2008) reported that low serum vitamin D concentrations were 
associated with an increased risk of death. In another study of 520 male 
patients with stage 3-5 CKD, not yet on dialysis, treatment with oral calcitriol 
was associated with better survival. The incident rate ratio for mortality in 
patients treated with calcitriol compared to untreated patients was 0.35 (95% 
CI, 0.23-0.54; p<0.001) and for the combined endpoint of death and dialysis 
initiation was 0.46 (95% CI, 0.35-0.61) (Kovesdy et al., 2008).  
 
Ravani et al. (2009) found in his study of 168 patients with CKD stages 2-5 
that the level of vitamin D decrease as GFR declines, and vitamin D is an 
independent inverse predictor of disease progression and death in patients 
with CKD stages 2-5. In addition, nutritional vitamin D supplementation in 
hemodialysis patients have shown various improvements in intermediate 
outcomes including increased circulating vitamin D and albumin 
concentrations as well as decreased calcium, PTH, inflammatory cytokines, 
left ventricular mass index, and erythropoietin stimulating agent dose (Matias 
et al., 2010 and Stubbs et al., 2010). In this context, small randomized trials 
have found that treatment with active vitamin D  analogs decreases 
proteinuria and delays progression of kidney disease in patients with mild to 
moderate CKD (de Zeeuw et al., 2010). 
 
The classic biochemical abnormalities in CKD–mineral bone disease are 
hypocalcemia, hyperphosphatemia, hyperparathyroidism, hypovitaminosis D 
and elevated fibroblast growth factor-23 (Cunningham et al., 2011). In a 
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cohort study of 1,099 advanced CKD patients, Kendrick et al. (2012) found 
that only 17.2% of subjects had vitamin D concentrations greater than 30 
ng/ml, whereas 69.4% had plasma vitamin D concentration ranging between 
10-30 ng/ml; the remaining 13.4% were severely vitamin D-deficient (<10 
ng/ml). In this regard, Nigwekar et al. (2012); Rozita et al. (2013) and Kim 
and Kim. (2014) reported that vitamin D deficiency or insufficiency is common 
in patients with CKD, and serum levels of vitamin D appear to have an inverse 





























3.1 Study design 
The present study is a case-control investigation. Case-control studies are 
often used to identify factors that may contribute to a medical condition by 
comparing subjects who have that condition/disease (the "cases") with 
subjects who do not have the condition/disease but are otherwise similar (the 
"controls"). Case-control studies are quick, widely used, relatively inexpensive 
to implement, require comparatively fewer subjects, and allow for multiple 
exposures or risk factors to be assessed for one outcome (Mann, 2003 and 
Song and Chung, 2010). 
 
3.2 Study population 
The study population comprised CKD patients aged 40-65 years attending 
Kidney unit at Al-Shifa hospital and Nasser Medical Complex in Gaza strip. 
Control group was apparently healthy persons. 
3.3 Sample size and sampling 
CKD patients aged 40 to 65 years were taken from Kidney unit at Al-Shifa 
hospital and Nasser Medical Complex in Gaza Strip. Control healthy 
individuals were selected from the general population. Cases and controls 
were matched for age and gender. The sample size calculations were based 
on the formula for case-control studies. EPI-INFO statistical package version 
3.5.1 was used with 95% CI, 80% power and 50% proportion as conservative 
and OR > 2. The sample size in case of 1:1 ratio of case control was found to 
be 40:40. For a no-response expectation, the sample size was increased to 





3.4 Exclusion criteria 
 Cases and controls whose aged under 40 years and above 65 years 
old. 
 Pregnant women. 
 Subjects with history of cancer. 
 Patients with  other chronic diseases such as diabetes . 
 Patients who take hormone replacement therapy or corticosteroid 
therapy. 
3.5 Ethical consideration 
The necessary approval to conduct the study was obtained from Helsinki 
committee in the Gaza Strip.  
 
3.6 Data collection 
3.6.1 Questionnaire interview 
A meeting interview was used for filling in a questionnaire which designated 
for matching the study need (Annex 1). All interviews were conducted face to 
face by the researcher herself. During the study the interviewer explained to 
the participants any of the confused questions that will not clear to them. Most 
questions were the yes/no question which offers a dichotomous choices and 
multiple choice (Backestrom and Hursh-Cesar, 2012). The validity of the 
questionnaire was tested by six specialists in the fields of nephrology, 
epidemiology, public health, biochemistry and nutrition. The questionnaire was 
piloted with 8 patients not included in the study. The questionnaire included 
questions on sociodemographic data (Age, education, employment, family 
income/month and family history of CKD), life style (Smoking, diet, physical 
activity), and clinical data (Age at diagnosis and duration of CKD). 
 
3.6.2 Body mass index 
Body mass index was calculated as the ratio of body weight in Kg/height in 
square meter. Medical balance (Seca Model 762, Germany) was used for 
weight measurement. People with BMI=18.5-24.9 were considered to have 
28 
 
normal weight, people with BMI=25.0-29.9 were classified overweight, people 
with BMI≥30.0 were considered obese (WHO, 2012). 
 
3.6.3 Blood collection and processing 
Blood samples were collected from 42 CKD patients and 42 controls. Fasting 
overnight venous blood sample (about 6 ml) was drawn by the researcher 
herself into vacutainer tubes from each control and CKD individuals. The 
blood was left for a while without anticoagulant to allow blood to clot. Then 
serum samples were obtained by centrifugation at room temperature at 4000 
rpm/10 minutes for biochemical analysis.  
 
 
3.7 Biochemical analysis 
3.7.1 Determination of serum vitamin D 
25-hydroxy (25-OH) Vitamin D enzyme linked immunoassay (ELISA) is 
designed by Calbiotech, Inc for the quantitation of total 25-OH Vitamin D in 
human serum and plasma (Bikle, 2010). 
 
Principle  
The kit is a solid phase (ELISA), based on the principal of competitive binding. 
Anti-Vitamin D antibody coated wells are incubated with Vitamin D standards, 
controls, samples, and Vitamin D-Biotin conjugate at room temperature for 90 
minutes. During the incubation, a fixed amount of biotin-labeled vitamin D 
competes with the endogenous Vitamin D in the sample, standard, or quality 
control serum for a fixed number of binding sites on the anti-Vitamin D 
antibody. Following a wash step, bound Vitamin D-Biotin is detected with 
Streptavidin-HRP (Horseradish peroxidase). Streptavidin-HRP conjugate 
immunologically bound to the well progressively decreases as the 
concentration of Vitamin D in the specimen increases. Unbound SA-HRP 
conjugate is then removed and the wells are washed. Next, a solution of TMB 
(Tetramethylbenzidine) Reagent is added and incubated at room temperature 
for 30 minutes, resulting in the development of blue color. The color 
development is stopped with the addition of stop solution, and the absorbance 
is measured spectrophotometrically at 450 nm. A standard curve is obtained 
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by plotting the concentration of the standard versus the absorbance. The color 
intensity will be inversely proportional to the amount of 25 (OH)D in the 
sample. The assay measures both Vitamin D2 and D3. The total assay 
procedure run time is 2.5 hours. 
 
Composition of reagents 
Materials provided 96 Tests 
Microwell plate coated with anti Vitamin D 12x8x1 
Vitamin D Standard Set: 7 vials (ready to use)  0.25 ml 
Vitamin D Control Set: 2 vials (ready to use)  0.25 ml 
Biotinylated 25 (OH)D Reagent: 1 Vial (51X)  0.5 ml 
Assay Diluent, 1 bottle 24 ml 
Streptavidin-HRP, 1 bottle (ready to use)  23 mL 
Stop Solution, 1 bottle (ready to use)  12 mL 
TMB Substrate, 2 bottles (ready to use)  2 x 12 ml 
Microplate sealing film  2 
Wash Concentrate 20X, 1 bottle 25 ml 
 
 
Preparation of reagent 
Before running the test, prepare the following: 
1. Standards and Reagents: 
Standards are serum-based solutions and stable when stored at -2-8°C,  
protected from light, until the expiration date on the label. Equilibrate the 
needed volume of standards and reagents to room temperature before use. 
2. 51X Biotin conjugate: Immediately before use, prepare 1X working solution 
at 1:51 with assay diluent (e.g. Add 0.1ml of the 50x Vitamin D-Biotin  
conjugate concentrate to 5ml of assay diluent). Remaining Assay Diluent must 
be stored at 2-8°C in dark and tightly capped. 
3. Prepare 1X Wash Buffer by adding the contents of the bottle (25 ml, 20X) to 
475 ml of distilled or deionized water. Store at room temperature (18-24°C). 
 
Analytical procedure 
All reagents and specimens must be allowed to come to room temperature 
before use. All reagents must be GENTLY mixed without foaming. Once the 
procedure has started, all steps should be completed without interruption. 




2. Dispense 200l working solution of biotinylated 25(OH)D reagent, into each 
well. 
3. Carefully mix the contents in the wells for 20 seconds using a plate shaker 
at 200-400 rpm (or equivalent motion). Remove from shaker and cover the 
plate with the adhesive plate seal making sure there is a complete seal over 
each well. 
4. Incubation #1 – Incubate sealed plate for 90 minutes at room temperature. 
5. Carefully remove the plate seal. 
6. Briskly shake out the contents of the wells into a waste reservoir. 
7. Wash# 1 - Dispense 300l of 1X Wash Buffer into each well, and then 
briskly shake out the 1X Wash Buffer into a waste reservoir. Strike the wells 
sharply on absorbent paper to remove residual droplets. Repeat 2 more times 
for a total of 3 washes. 
8. Dispense 200l of enzyme conjugate (Streptavidin-HRP) into each well. 
9. Incubation #2 - Incubate for 30 minutes, at room temperature. 
10. Briskly shake out the contents of the wells into a waste reservoir. 
11. Wash # 2 - Dispense 300l of 1X Wash Buffer into each well, and then 
briskly shake out the 1X Wash Buffer into a waste reservoir. Strike the wells 
sharply on absorbent paper to remove residual droplets. Repeat 2 more times 
for a total of 3 washes. 
12. Using a multi-channel pipette, dispense 200 l of TMB Substrate into each 
well. 
13. Incubation #3 - Incubate for 30 minutes at room temperature, preferably in 
the dark. 
14. Stop - Dispense 50 l of Stop Solution into each well to stop the 
enzymatic reaction. Carefully mix plate contents for 20-30 seconds. 
15. Read absorbance on ELISA Reader at 450 nm within 10 minutes of 




Deficient (<10 ng/dl) 
Insufficient (10-30 ng/dl) 
Sufficient (>30 ng/dl) 
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3.7.2 Determination of serum urea 
Serum urea is determined by using colorimetric test (Fawcett and Scott, 
1960) using DiaSys reagent kits.   
Principle 
Urea + 2H2O           2NH3 + H2CO3 
 
2-Oxoglutarate + NH3 + NADH    →       L-Glutamate + NAD









≥ 0.6 ku/l 






0.25 mmol/l R2: NADH 
50 mg/dl Standard 
 
Assay procedure 
The working solution was prepared by mixing 4 parts of R1 with 1 part of R2.  
Wavelength: 340 nm 
Optical path: 1cm 
Temperature: 37 ºC 





 Ten microliters of standard (sample or control) was added to 1ml of 
working reagent and mixed well. 
 The mixture was incubated for 30 sec then absorbance (A1) was 
recorded. 
 After exactly further 60 sec the absorbance (A2) was measured. 
Calculation 
∆A = (A2 –A1) sample or standard 
Urea (mg/dl) =  
 
Reference value  
(Palestinian Clinical Laboratory Tests Guide, PCLTG, 2005) 
Adult 13 - 43 mg/dl 
 
 
3.7.3 Determination of serum creatinine  
Serum creatinine was determined by using kinetic test without 
deproteinization according to Newman and Price method (Newman and 
Price, 1999) using DiaSys reagent kits. 
Principle 
Creatinine forms a colored orange-red complex in an alkaline picrate solution. 
The difference in absorbance at fixed times during conversion is proportional 
to the concentration of creatinine in the sample. 











Concentrations are those in the final test mixture. 
Concentration Reagent 
0.16 mol/l R1: Sodume hydroxide (pH approx. 13) 
4.0 mmol/l R2: Picric acid (pH approx. 1.2) 
2.0 mg/dl Standard 
 
Assay procedure 
The working solution was prepared by mixing 4 parts of R1 with 1 part of R2.  
Wavelength: 490 nm 
Optical path: 1cm 
Temperature: 37 ºC 
Measurement: against distilled water. 
 Fifty microliters of standard (sample or control) was added to 1ml of 
working reagent and mixed well. 
 The Mixture was incubated for 60 sec then absorbance (A1) was 
recorded. 
 After exactly further 120 sec the absorbance (A2) was measured. 
 
Calculation 











Reference value (in serum) (PCLTG, 2005) 
Adult:  M 
            F 
0.6 - 1.2 mg/dl 
0.5 - 1.1 mg/dl 
 
3.7.4 Determination of serum uric acid 
Serum uric acid is determined by enzymatic photometric test with TBHBA 
(2,4,6-tribromo-3-hydroxybenzoic acid) (Fossati et al., 1980) using DiaSys 
reagent kits.  
 
Principle: 
Uric acid is oxidized to allantoin by uricase. The generated hydrogen peroxide 
reacts with 4-aminoantipyrine and 2,4,6-tribromo-3-hydroxybenzoic acid 
(TBHBA) to quinoneimine.  
 
Uric acid + H2O + O2                                       Allantoin + CO2 + H2O2 
 







Reagent Components Concentrations 
Reagent 1 












 100 mmol/l 
0.3 mmol/l 
10 μmol/l 
≥ 2 kU/L 
≥ 30 U/L 




The reagents are ready to use.  
Sample start: 
Mix 4 part of R1 with 1 part of R2 (e.g. 20 ml R1 + 5 ml R2) = monoreagent. 
This reagent is stable for 3 months if stored at +2 to +8 0C, and for 2 weeks if 




Reagent Blank Sample or Standard 
Sample or Standard - 20μ 
Dist. Water 20μ - 
Reagent 1 1000μ 1000μ 
Mix, incubate 5 min, then add: 
Reagent 2 250μ 250μ 
Mix, incubate 30min. at 20 – 25 oC or 10 min. at 37 oC. Read the 





Reagent Blank Sample or Standard 
Sample or Standard - 20μ 
Dist. Water 20μ - 
Monoreagent 1000μ 1000μ 
Mix, incubate 30min. at 20 – 25 oC or 10 min. at 37 oC. Read the 





With standard or calibrator 
 
Uric acid [mg/dl] = 
∆A Sample 
X Conc. of Std/Cal [mg/dl] 
∆A Std/Cal 
 
Reference value (in serum)  
Adult:  M 3.4-7.0 mg/dl 
            F 2.4-6.0  mg/dl 
 
3.7.5 Determination of serum total protein 
Serum total protein was determined by photometric test according to Thomas 




Protein together with copper ions form a violet blue colour complex in alkaline 




























Sodium hydroxide  
 





5 g/dl Standard 
 
Mono reagent preparation 
 





Sample Blank  
1000 μl 1000 μl Monoreagent 
20 μl - Sample 
- 20 μl Dist. Water 
 
Mix, incubate for 5 min at 25°C and read absorbance against the reagent 




The protein concentration in the sample is calculated using the following 
general formula: 
Total protein [g/dL] =  (Δ A sample ) X Conc. St [g/dl] 
                                   (Δ A standard) 
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Reference value (in serum)  
Adult 6.4-8.3 g/dl 
 
3.7.6 Determination of serum albumin 
Serum albumin was determined by photometric test according to the method 
described by Johnson and his colleagues (Johnson et al., 1999) using 




Serum albumin in the presence of bromocresol green at a slightly acid pH 














Sample Blank  
1000 μl 1000 μl Reagent 
10 μl - Sample 
- 10 μl Dist. Water 
 
Mix, incubate for approx. 10 min. The absorbance was read against reagent 





Serum albumin concentration in the sample is calculated using the following 
general formula: 
 
Albumin [g/dL] = (Δ Asample) X Conc. Std [g/dl] 
                         (Δ AStandard) 
 
Reference value (in serum)  
Adult 3.5-5.0 g/dl 
 
3.7.7 Determination of serum globulin 
Globulin was calculated according the following formula:  
 
Globulin = Total protein – Albumin. 
 
3.7.8 Determination of serum calcium 
Serum calcium was determined by photometric test with cresolphthalein 
complexone (Thomas, 1998) using DiaSys reagent kits. 
 
Principle 
Cresolphthalein complexone reacts with calcium ions in alkaline medium 
forming a red-violet color. Interference by magnesium is eliminated by addition 
of 8-hydroxy-quinoline. 
Reagents 
Reagent Components Concentrations 
Reagent 1 Ethanolamine Detergent 
pH 10.7 
600 mmol/L 
Reagent 2 2-Cresolphthalein complex 
8-Hydroxyquinoline 






Reagent 3 Standard  10 mg/dL 
 
Preparation and stability of working reagent 
Four parts of R1 were mixed with 1 part of R2 
Stability: 3 days at 2-8 oC 
Procedure 
Wavelength  570 nm, Hg 578 nm (550-590 nm) 
Temperature  37°C 
Cuvette  1 cm light path 
Reading against reagent blank was done 


















Mixing and reading the optical density (OD) after 5 minute incubation was 




X n = sample calcium concentration (mg/dl) 
OD Standard 




Reference value (in serum)  
Adult 8.9-10.1 mg/dl 
 
3.7.9 Determination of serum phosphorus 
Serum phosphorus was determined by phosphomolybdate UV end point  
(Tiez, 1994) using Ammonium Molybdate Diagnostic K. 
 
Principle 
Determination of inorganic phosphate was made according to the following 
reaction:      
 Phosphorus 




Reagent Components Concentrations 




Standard Phosphorus  5 mg/dl 
 
Preparation and stability of working reagent 
The reagent is ready for use 
 
Procedure: 
Wavelength  340 nm 
Temperature  37°C 
Cuvette  1 cm light path 
 






















Mixing and reading the optical density (OD) after a 5 minute incubation was 




X n =   sample phosphorus concentration (mg/dl) 
OD Standard 
         n = standard phosphorus concentration 
 
Reference value (in serum)  










3.8 Statistical analysis 
Data were computer analyzed using SPSS/ PC (Statistical Package for the 
Social Science Inc. Chicago, Illinois USA, version 18.0) statistical package. 
 Simple distribution of the study variables and the cross tabulation were 
applied.  
 Chi-square (2) was used to identify the significance of the relations, 
associations, and interactions among various variables. Yates’s 
continuity correction test, 2 (corrected), was used when not more than 
20% of the cells had an expected frequency of less than five and when 
the expected numbers were small.  
 The independent sample t-test procedure was used to compare means 
of quantitative variables by the separated cases into two qualitative 
groups such as the relationship between cases and controls vitamin D. 
 The one-way ANOVA test was used for analysis of variance. 
 Pearson's correlation test was applied.  
 The results in all the above mentioned procedures were accepted as 
statistical significant when the p-value was less than 5% (p<0.05). 
 Range as minimum and maximum values was used.  
 The percentage difference was calculated according to the formula: 
Percentage difference equals the absolute value of the change in 
value, divided by the average of the 2 numbers, all multiplied by 100. 
Percent difference = (| (V1 - V2) | / ((V1 + V2)/2)) X 100. 
 SPSS program version 18.0 was also used for correlation graph 
plotting between vitamin D and other studied parameters as well 










4.1 Personal profile of the study population 
Table 4.1 summarizes personal profile of the study population. The study 
included 42 cases (21 males and 21 females) and 42 controls (21 males and 
21 females). Age classification showed that 10 (23.8%) cases and 12 (28.5%)  
controls were ≤45 years old. Age group 46-55 years comprised 15 (35.7%) 
cases and 16 (38.1%) controls. Cases and controls aged >55 years old were 
17 (40.4%) and 14 (33.3%), respectively. The difference between cases and 
controls in term of age distribution was not significant (2=0.504, P=0.776). 
The mean ages of cases and controls were 55.3±8.6 and 54.9±8.2 years old 
with ranges of 40-65. The independent sample t-test also showed no 
significant difference between mean ages of cases and controls (t=0.305, 
P=0.761). Analysis of the educational status of the study population showed 
that 7 (16.6%) cases and 6 (14.3%) controls had a university degree, 3 
(7.14%) cases and 6 (14.3%) controls had finished secondary school, 8 
(19.0%) cases and 12 (28.5%) controls had finished preparatory school, 9 
(21.4%) cases and 11 (26.2%) controls had passed primary school, and 15 
(35.7%) cases and 7 (16.6%) controls were illiterate. The difference between 
various educational levels of cases and controls was not significant 















Table 4.1 Personal profile of the study population 


































Mean±SD 55.3±8.6 54.9±8.2 T 0.305 0.761 

























Secondary school  
Preparatory school 


































  0.529* 
*P-value of 
2
 (corrected) test. 
P>0.05: not significant. 
 
4.2 Socioeconomic data of the study population  
Socioeconomic data of the study population is provided in Table 4.2. The 
employed cases and controls were 12 (28.5%) and 22 (52.3%) whereas 30 
(71.4%) cases and 20 (47.6%) controls were unemployed. The difference 
between the two groups was significant (2=4.941, P=0.026). Regarding family 
income\month, significant difference was also recorded between cases and 
controls (2=7.939, P=0.019) with CKD more frequent among families with low 
income. Family history of CKD revealed that 11 (26.1%) cases and 3 (7.14%) 
controls reported that they had family history of CKD whereas 31 (73.8%) 
cases and 39 (42.8%) controls had not (2(corrected)=4.200, P=0.040) indicating 
that family history is associated with CKD. In addition, 8 (19.0%) cases were 











Table 4.2 Socioeconomic data of the study population 



























































































Table 4. 1 
*NIS: new Israeli Shekels. *P-value of 
2
 (corrected) test. 
P<0.05:Significant,  P>0.05:not significant 
 
4.3 Duration of chronic kidney disease and its 
distribution among patients  
The mean duration of CKD among patients was 9.3±10.4 years. The 
distribution of CKD among patients by the duration of the disease is 
demonstrated in Table 4.3. Patients with CKD 1-10 years were 29 (69.0%), 
whereas those with CKD duration of 11-20 years were 7 (16.6%). The rest 
of patients 6 (14.2%) had CKD for more than 21 years. 
Table 4.3 Distribution of CKD among patients (n=42) by the duration of the 
disease. 
Duration of CKD (Year) No. %  
1-10 29 69.0 
11-20 7 16.6 








4.4 Body mass index of the study population 
Table 4.4 shows BMI of the study population. The mean weight of cases 
compared to controls were 75.1±15.1 versus 77.8±16.2 kg, % difference=        
-3.53, t=0.795 and P=0.429. The mean height of cases compared to controls 
were 1.65±0.1 versus 1.68±0.08 meter, % difference=-1.80, t=1.452 and 
P=0.150. Therefore, BMI of cases and controls were 27.6±5.2 and 27.4±4.1 
kg/m2, respectively, % difference=0.73 and t=0.164 and P=0.870. 





























0.73 0.164 0.870 
*Kg: kilogram, **m: meter. ***BMI (Kg/m
2
): People with BMI=18.5-24.9 were considered to have 
normal weight, people with BMI=25.0-29.9 were classified overweight, people with BM≥30.0 were 
considered obese (WHO, 2012). P>0.05: not significant. 
 
 
4.5 Serum vitamin D level of the study population 
Table 4.5 and Figure 4.1 show the mean level of serum vitamin D of the study 
population. There was a significant decrease in the mean level of vitamin D in 
cases compared to controls (29.7±12.9 versus 35.2±9.9 ng/dl, % difference=  
-16.9, t=2.171 and P=0.033). 
Table 4.5 Serum vitamin D levels of the study population. 






















4.6 Categories of serum vitamin D levels of the study 
population 
As illustrated  in Table 4.6 and Figure 4.2, serum vitamin D level of the study 
population were classified  into 3  different categories: deficient (<10 ng/dl), 
insufficient (10-30 ng/dl) and sufficient (>30 ng/dl). The number of cases 
having vitamin D deficient, insufficient and sufficient were 6 (14.3%), 17 
(40.5%) and 19 (45.2%), respectively compared to controls of 1 (2.4%),10 
(23.8%) and 31 (73.8%), respectively with 2(corrected)=6.039 and P=0.042. 
 
Table 4.6 Different categories of serum vitamin D levels of the study 
population. 







No. % No. % 




Insufficient (10-30 ng/dl) 17 40.5 10 23.8 
Sufficient (>30 ng/dl) 19 45.2 31 73.8 
*P-value of 
2






























Figure 4.1 Serum vitamin D levels of cases (n=42) 






4.7 Kidney function of the study population  
The concentration of serum urea, creatinine and uric acid as an indicator of  
kidney function are illustrated in Table 4.7. Urea, creatinine and uric acid 
concentrations were significantly higher in cases than in controls (84.6±47.4 
and 1.90±1.20 and 7.92±2.29 versus 35.7± 13.5 and 0.81±0.27 and 5.18±2.31 
mg/dl, % differences 81.3, 80.4 and 41.8, P=0.000, respectively).   
 






  Mean ±SD 
% 
Difference 
























41.8 5.428 0.000 





































Figure 4.2: Different categories of serum vitamin D levels of cases 





4.8 Glomerular filtration rate of the study population 
Table 4.8 shows GFR of the study population. The mean GFR was significantly 
decreased in cases compared to controls (62.4±32.5 versus 124.6±45.4 
ml/min/1.73m2), recording % difference of -66.5, t=7.114 and P=0.000. 
 


















-66.5 7.114 0.000 
GFR was calculated from Schwartz equation (NKF, 2002). GFR (ml/min/1.73m²) = 0.55 × 
length  ∕ Scr. P<0.05: Significant. 
 
 4.9 Serum protein profile of the study population 
Table 4.9 shows serum total protein, albumin and globulin concentrations of 
the study population. The mean concentrations of total protein and albumin 
were significantly decreased in cases compared to controls (7.0±0.5 and 
5.2±0.40 versus 7.3±0.6 and 5.4±0.59 mg/dl), recording % difference of -4.2 
and -3.8, t=2.928 and t=2.316 and P=0.005 and P=0.023, respectively. 
Similarly, serum globulin was decreased in cases compared to controls but 
















Table 4.9 Serum total protein, albumin and globulin concentrations of the 
study population 
 
P<0.05: Significant, P>0.05: not significant. 
 
4.10 Serum calcium and phosphorus of the study 
population 
Table 4.10 shows serum calcium and phosphorus concentrations of the study 
population. The mean concentration of serum calcium was significantly 
decreased in cases compared to controls (8.61±0.77 versus 9.12±0.69 mg/dl), 
recording % difference of -5.8, t=3.221 and P=0.003. On the other hand, 
serum phosphorus concentration exhibited no significant difference between 
cases and controls (4.72±0.94 versus 4.49±0.85, % difference=4.9, t=1.186 
and P=0.239). 
 
Table 4.10 Serum calcium and phosphorus concentrations of the study 
population 
Electrolyte  
      (mg/dl) 
Case (n=42)  
    mean±SD 
Control (n=42) 


















4.9 1.186 0.239 



































-5.3 0.728 0.469 
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4.11 Relations of vitamin D 
4.11.1 Serum vitamin D level in relation to sociodemographic 
data of the study population 
Table 4.11 shows the relationship between sociodemographic data and serum 
vitamin D level of the study population. Serum vitamin D level was significantly 
lower in individuals who reported family history of CKD than who did not 
(26.1±13.6 versus 33.2±11.5, t=2.167, P=0.038), implying that vitamin D level 
is associated with family history of the disease. On the other hand, there were 
no associations between vitamin D and employment or family income.    
Table 4.11 Serum vitamin D level in relation to sociodemographic data of the 
study population 
Sociodemographic data Vitamin D 
Mean±SD 







































P<0.05: Significant and P>0.05: Not significant. 
 
 
4.11.2 Vitamin D level in relation to CKD duration among the 
study population 
Table 4.12 shows a progressive decrease in serum vitamin D level with 
increasing the duration of CKD. However, this inverse relationship was not 









Table 4.12 Serum vitamin D level in relation to CKD duration among the study 
population 
Duration of CKD 
(Year) 





1-10 29 37.0±12.8  
2.048 
 
0.143 11-20 7 34.7±11.3 
21-34 6 26.4±13.2 
P>0.05: Not significant. 
 
4.11.3 Vitamin D levels in relation to urea, creatinine and uric 
acid of the study population 
Vitamin D levels in relation to urea, creatinine and uric acid of the study 
population is provided in Table 4.13 and Figure 4.3. Vitamin D showed negative 
significant correlations with urea, creatinine and uric acid levels (r=-0.302, r=      
-0.343 and r=-0.249; P=0.005, P= 0.001 and P=0.022, respectively).  
 
Table 4.13 Serum vitamin D levels in relation to urea, creatinine and uric acid of 
the study population 
Parameter 
 (mg/dl) 




Urea  -0.302 0.005 
Creatinine 




























Figure: 4.3. Serum vitamin D levels in relation to urea, creatinine and uric acid of the 
study population.  
 
4.11.4 Vitamin D level in relation to GFR of the study 
population 
Vitamin D level in relation to GFR of the study population is provided in Table 
4.14 and Figure 4.4. Vitamin D showed a positive significant correlation with 
GFR level (r=0.258, P=0.020). 
 








GFR 0.258 0.020 









Figure: 4.4. Serum vitamin D level in relation to glomerular filtration rate (GFR) of the 
study population.  
 
 
4.11.5 Vitamin D levels in relation to protein profile of the 
study population 
Vitamin D levels in relation to total protein, albumin and globulin of the study 
population is illustrated in Table 4.15 and Figure 4.5. Vitamin D showed positive 
significant correlations with total protein and albumin levels (r=0.283, P=0.011 
and r=0.278, P=0.012, respectively). However, a positive none significant 
correlation was recorded between vitamin D and globulin level (r=0.159, 
P=0.156).   
 
Table 4.15 Serum vitamin D levels in relation to total protein, albumin and 








Total protein  0.283 0.011 
Albumin 

















Figure: 4.5. Serum vitamin D levels in relation to total protein, albumin and globulin 
concentrations of the study population.  
 
 
4.11.6 Vitamin D levels in relation to calcium and phosphorus 
of the study population 
Vitamin D levels in relation to calcium and phosphorus of the study population is 
presented in Table 4.16 and Figure 4.6. Vitamin D showed a positive significant 
correlation with calcium level (r=0.562, P=0.001). However, a negative none 
significant correlation was recorded between vitamin D and phosphorus level 
(r=-0.168, P=0.125).   
 









Calcium  0.562 0.001 
Phosphorus  -0.168 0.125 







Figure: 4.6. Serum vitamin D levels in relation to serum calcium and phosphorus 









Chronic kidney disease is a serious health problem globally as well as in 
Palestine. The prevalence of CKD among adults was estimated at 7.7-13% 
worldwide (Gouda et al., 2011; Nakai et al., 2013 and CDC, 2014). In most 
cases, CKD patients end with renal failure (U.S. Renal Data System, 
USRDS, 2009). The total prevalence of ESRD among Palestinian patients 
was 240.3 people per million population (Khader et al., 2013). Despite that, 
the published data on the disease were few in the Gaza strip and most of 
information emerged as annual reports produced by the Palestinian Ministry of 
Health. The available biochemical tests of CKD were limited to routine 
traditional kidney function including urea and creatinine tests when the patient 
visited the clinic. This necessitated further assessment of other biochemical 
features in blood such as vitamin D, its deficiency was recently linked to CKD 
(Cunningham et al., 2011; Satirapoj et al., 2013 and Obi et al., 2015). 
Therefore, supplementation of vitamin D to CKD patients in the Gaza 
hospitals and clinics may be useful in the disease management. 
 
5.1 Sociodemoghraphic data of the study population 
The present study is a case-control investigation included 42 CKD patients 
(21 males and 21 females) with mean age 55.3±8.6 years and 42 controls (21 
males and 21 females) with mean age 54.9±8.2 years. Chronic kidney 
disease was more prevalent among unemployed cases compared to their 
counterparts of controls. Similar results were previously documented by White 
et al. (2008) and Abu Nada, (2012) who showed that unemployment 
increased the incidence of CKD. Regarding family income, CKD was more 
prevalent among families with less income/month. This result is in agreement 
with that obtained by NKF, (2002) and Bello et al. (2008) who pointed out 
that low income was associated with greater impairments' in functioning and 
well-being in patients with CKD. In addition, Zhang et al. (2012) reported that 
the prevalence of CKD varied greatly between geographical regions and this 
might be related to variability in lifestyles and economic development. 
Furthermore, family history of CKD was reported by higher number of cases 
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than controls, indicating that family history is associated with CKD. Such 
finding is in accordance with other studies (Johnson, 2012 and CDC, 2014).  
 
5.2 Duration of chronic kidney disease and its 
distribution among patients 
Data presented in this study showed that more than two thirds of cases had 
CKD since 10 years or less. This confirmed the idea that CKD has long 
asymptomatic preclinical phase which frequently goes undetected, particularly 
in developing world where CKD is prevalent and most of people did not had 
routine medical examination (Nigwekar et al., 2014). 
 
5.3 Serum vitamin D levels of the study population 
The present results revealed that the number of cases having vitamin D 
deficiency and insufficiency were significantly higher than that of controls. 
Vitamin D deficiency and insufficiency were found to be prevalent among CKD 
patients (Kendrick et al., 2012 and Satirapoj et al., 2013). When compared 
with controls, cases showed significant decrease in the mean level of serum 
vitamin D. This means that deficiency in vitamin D levels are linked to CKD. In 
consistent with this result, the prevalence of vitamin D deficiency has been 
reported in CKD patients (Holick, 2007; de Boer et al., 2011 and Obi et al., 
2015). In addition, Pilz et al. (2011) concluded that supplementation of 
vitamin D is associated with a lower risk of CKD. The kidney plays a central 
role in vitamin D metabolism and regulation of its circulating levels (Kannan 
and Lim, 2014 and Obi et al., 2015). Therefore, impaired renal function may 
lead to vitamin D deficiency, as has been found in patients with CKD.  
 
Several mechanisms involved in decreased production of vitamin D that occur 
in CKD were proposed:  
1. Decrease in GFR may limit the delivery of vitamin D substrate 25(OH)D to 
1α-hydroxylase enzyme, resulting in reduced production of vitamin D (Dusso 
et al., 2011). The significant decrease in GFR recorded in the present study 
do coincides with this view.  
2. Downregulation of renal 1α-hydroxylase may be attributed to a) 
hyperphosphatemia resulting from persistent phosphate retention, b) 
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increased fibroblast growth factor-23 due to declining kidney function, c) 
acidosis, hyperuricemia and uremia (Gutierrez et al., 2005; Usatii et al., 
2007 and Kuro, 2011). 
3. A decrease in renal mass as reported in CKD may limit the amount of 1α-
hydroxylase enzyme available for the production of vitamin D (Andress, 
2006). 
4. Alterations in cytochrome P 450 enzymes (CYP enzymes) abundance 
(Bosworth and de Boer, 2013). 
 
When related to family history, vitamin D levels were found to be significantly 
lower in individuals who reported family history of CKD than who did not. This 
indicates that CKD patients with family history of the disease are more likely to 
develop vitamin D deficiency. In this instance, vitamin D supplementation to 
such patients could be useful. Its accepted that vitamin D treatment improves 
CKD (Pilz et al., 2011 and Kim and Kim, 2014). Concerning CKD duration, 
the present results revealed that vitamin D level was inversely related to CKD 
duration. Ravani et al. (2009) showed that serum vitamin D is an inverse 
predictor of kidney disease progression. 
 
5.4 Kidney function of the study population 
Urea, creatinine and uric acid were significantly increased in cases compared 
to controls whereas GFR was significantly decreased. Similar results were 
documented (Chen et al., 2009; Renal Resource Center, 2010 and Abu 
Nada, 2012). Accumulation of urea, creatinine and uric acid in the blood is a 
predictable consequence of progressive decline of GFR as CKD proceeded. 
Pearsons correlation test showed a significant negative correlation of vitamin 
D with urea, creatinine and uric acid, whereas strong positive correlation was 
recorded with GFR. Similar results were reported by kim and kim (2014). 
This implies that vitamin D deficiency is linked to kidney function. In addition, 
several observational studies have demonstrated an important link between 
vitamin D deficiency, impaired GFR, and increased mortality in patients with 





 5.5 Serum protein profile of the study population 
As illustrated in the present study, there was a significant decrease in the 
mean level of total protein and albumin in cases compared to controls. 
Similarly serum globulin was decreased without significance. These results 
are in agreement with that found by Levey (2002), and Abu Nada, (2012). It 
is known that, in CKD, there is a loss of serum protein and albumin in urine 
leading to proteinurea (Wen et al., 2008; Guh, 2010 and Campbell and 
Weir, 2015). In addition to its loss in urine, serum protein may breakdown to 
form urea that further contributing to elevation of serum urea concentration 
noted in CKD patients. When related to vitamin D levels, total protein and 
albumin showed significant positive correlations indicating that these 
parameters are interchangeable in CKD. However none significant positive 
correlation was found with globulin. Several studies have shown a correlation 
between vitamin D deficiency and an increased degree of albuminuria (de 
Boer et al., 2007 and Isakova et al., 2011).  
 
5.6 Serum calcium and phosphorus of the study 
population 
The mean concentration of serum calcium was significantly decreased in 
cases compared to controls whereas serum phosphorus concentration 
exhibited no significant increase between cases and controls. In this context, 
one can say that phosphate retention in the kidney can lead to a decrease in 
the serum calcium level. Hypocalcemia was reported in CKD (Wolf et al., 
2007 and Kalantar-Zadeh, 2008). Impairment in renal reabsorption of 
calcium could be stand behind hypocalcemia observed in CKD. When related 
to vitamin D level, serum calcium showed a positive correlation, whereas 
serum phosphorus displayed a negative correlation with vitamin D. These  
results are in agreement with that demonstrated by Sai et al. (2011) and 
Kendrick et al. (2012). Hypocalcemia accompanied with vitamin D deficiency 
may be attributed to the fact that vitamin D enhances intestinal calcium 







Conclusions and Recommendations 
6.1 Conclusions 
1. Chronic kidney disease was more prevalent among unemployed 
individuals, families with low income and individuals with family history of the 
disease. 
2. More than two-thirds of cases had CKD since 10 years or less. 
3. The mean level of serum vitamin D was significantly lower in cases 
compared to controls. The number of cases having vitamin D deficiency and 
insufficiency were significantly higher than that of controls. 
4. Urea, creatinine and uric acid concentrations showed significant increase in 
cases compared to controls, whereas GFR was significantly decreased in 
cases compared to controls. 
5. The mean levels of total protein and albumin were significantly lower in 
cases compared to controls. 
6. Serum calcium was significantly lower in cases compared to controls 
whereas, serum phosphorus showed none significant increase in cases. 
7. Serum vitamin D was found to be significantly lower in individuals with 
family history of CKD. 
8. Serum vitamin D showed significant negative correlations with urea, 
creatinine and uric acid and significant positive correlation with GFR. 
9. Serum vitamin D was positively correlated with total protein, albumin and 
globulin. 
10. Serum vitamin D exhibited significant positive correlation with calcium and 












1. Introducing of vitamin D test for CKD patients in Gaza hospitals is highly 
recommended. 
2. Frequent monitoring of vitamin D levels particularly in CKD patients 
especially those with family history of the disease. 
3. Supplementation of vitamin D to CKD patients could be useful in 




















I. Sociodemographic data 
1. Code number ………………  
2. Name (optional)  …………………    
3. Age in years ……….  
4. Sex                               a. Male                                          b. Female  
5. Education. 
a. illiterate    b. primary school    c. preperatary 
school           d. secondary school          e. University 
6. Employment                       a. Yes                      b. No                
7. Family income per month (shekel) 
 a. Less than 1000     b. 1000-2000       c. More than 2000 
8. Family history of chronic kidney disease ? 










9. Do you follow any particular diet? 
                                      a. Yes                   b. No 
10. Do you do physical activity? 
                                       a. Yes                     b. No 
 
 
III. clinical data 
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